Boehringer Ingelheim Animal Health Canada Inc. received approval from Health Canada to expand the label claim of NexGard® (afoxolaner) and NexGard Spectra™ (afoxolaner and milbemycin oxime) to include an indication for the reduction of B. burgdorferi infections as a direct result of killing adult I. scapularis vector ticks. B. burgdorferi is the infectious agent which causes Lyme disease in dogs.
NexGard® and NexGard Spectra™ are the first and only parasiticide products in Canada to receive a B. burgdorferi protection label claim. The label claim applies equally to both products because the concentration of afoxolaner is equivalent in both. This now provides the pet owner with heightened ability to prevent Lyme disease in their dog.
“Boehringer Ingelheim’s unwavering commitment to advancing veterinary medicine with a focus on prevention is proudly showcased with this first-ever indication in Canada to reduce the B. burgdorferi infections that cause Lyme disease,” says Tyron Hansen, Marketing Manager, Pet, Boehringer Ingelheim Animal Health Canada Inc. “Providing veterinarians and pet owners with reliable and effective products to keep their animals healthy remains our top priority.”
